PCOS Healthcare Trends · Evergreen explainer

PCOS and fertility: fewer ovulations, not a closed door

If you have PCOS and you are thinking about pregnancy, the internet tends to offer two extremes: alarm, or a supplement list. The evidence picture is calmer and more specific than either. PCOS, now also called PMOS for polyendocrine metabolic ovarian syndrome, affects fertility mainly because ovulation happens less often or not at all in some cycles, which means fewer chances to conceive across a year. It does not mean pregnancy is out of reach. This piece walks through what the 2023 International Evidence-based Guideline actually says about fertility workup and the order of care, what the largest trials reported in their own numbers, and what a 2026 re-analysis added about insulin resistance, so you can walk into a fertility appointment knowing what a complete conversation usually covers.

The one mechanism that explains most of it

Conception needs an egg to be released. Clinicians call a cycle with no egg released an anovulatory cycle, and call the broader pattern ovulatory dysfunction. It is one of the three features used to diagnose this condition, as our explainer on how PCOS/PMOS is diagnosed sets out, and our glossary defines ovulation and related terms in plain words.

When ovulation is irregular, the arithmetic is simple: fewer ovulatory cycles in a year means fewer chances, so conceiving can take longer even when nothing else is wrong. Top-ranking fertility explainers and the World Health Organization fact sheet they cite describe PCOS as the most common cause of anovulation worldwide. The same sources also make a second point that often gets lost: because the main barrier is ovulation itself, clinicians describe this cause of infertility as among the more treatable kinds. That is the framing the sources use. It is not a promise about any one person, and the sections below keep it that way.

A complete workup looks beyond PCOS

A common early mistake is to treat PCOS as the whole fertility story. The 2023 guideline describes a broader check before any conclusions are drawn:

Preconception health: the guideline list

Before trying to conceive, the guideline asks that a set of general health items be looked at for people with this condition: weight, blood pressure, smoking, alcohol use, diet and activity, sleep, and mental health. It also advises counselling on how weight can affect fertility and pregnancy, while noting that the evidence behind parts of that advice is of low certainty. Two fences belong around this list. First, it is a health review list, not a pass or fail test you must clear before anyone will help you. Second, it applies at any body size: our piece on lean PCOS explains why the same screening floor applies when weight is not part of the picture.

The order of care the guideline describes

The guideline describes care in steps, with lifestyle support alongside each step rather than as a hurdle before it. In its own wording, it names a medicine called letrozole as the first-line pharmacological treatment for ovulation induction in people with this condition who are not ovulating and who have no other infertility factors. It notes that this use is still off-label in many countries. It describes other medicines, procedures and in vitro fertilisation (IVF) as later options in the sequence when earlier steps do not lead to pregnancy or when other factors are present.

This page reports that order because patients deserve to know what guideline their clinician is working from. It does not recommend any step for you, it gives no doses, and it ranks nothing for your case. Which step, if any, fits depends on your full workup, your age, how long you have been trying, and your own priorities, decided with your clinician.

What the largest trial reported

The trial most often cited for the guideline position above is PPCOS II (Pregnancy in Polycystic Ovary Syndrome II), a United States trial that randomly assigned 750 women with PCOS to one of two ovulation medicines for up to five cycles. The researchers reported live births in 27.5 percent of the letrozole group and 19.1 percent of the comparison group, and ovulation in 61.7 percent of letrozole cycles compared with 48.3 percent of comparison cycles. Read those numbers the way researchers intend them: they are group results from one trial population, over a set number of cycles, in people who met that trial entry rules. They describe what happened on average in that study. They do not predict what will happen for you, and a single percentage from a headline is not a personal chance.

What a 2026 re-analysis added: insulin resistance before pregnancy

In 2026, researchers published a secondary analysis of the same PPCOS II trial data in Obstetrics and Gynecology, asking whether insulin resistance measured before pregnancy was linked to outcomes. Among 746 women, they reported that higher pre-pregnancy insulin resistance (grouped by a measure called HOMA-IR) was associated with lower ovulation rates (93.5 percent in the lowest group compared with 73.8 percent in the highest), lower clinical pregnancy and live birth rates, later first ovulation, and a higher recorded rate of gestational diabetes (13.8 percent in the lowest group compared with 45.7 percent in the highest). They also reported that improvement in the insulin resistance measure during treatment was associated with higher odds of clinical pregnancy in that dataset.

The authors conclusion, in their own framing, is that assessing insulin resistance before conception may matter for reproductive success and pregnancy risk. Note what kind of finding this is: a secondary analysis looks back at data collected for an earlier question, so it shows associations in that group, not proof that changing one number will change an outcome for a given person. Its practical use at an appointment is narrow and real: it is one more reason the guideline glucose checks described above belong in a fertility workup conversation.

If pregnancy happens: closer monitoring is part of the guideline picture

The 2023 guideline treats PCOS as a higher-risk status in pregnancy and asks that it be flagged in prenatal care, with monitoring and support to match. The risks it lists as higher include greater pregnancy weight gain, miscarriage, gestational diabetes, high blood pressure conditions including preeclampsia, preterm birth and caesarean delivery. That list is a reason for early booking and planned checks, not a forecast: many pregnancies in people with this condition proceed without those complications, and the guideline point is that the care team should know the history from the start. Our queued companion piece on PCOS and pregnancy will cover that monitoring in more depth.

What this does not mean

Questions to bring to a fertility visit

What this means when you are finding care

Fertility care for this condition usually sits with a reproductive endocrinologist, often alongside your obstetrician-gynaecologist and, for the metabolic side, an endocrinologist or your primary clinician. The clinician you want can show you the whole workup, not just the PCOS part, and can state the timeline and the next-step triggers in plain words. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state, for example the Florida listings page, and skim the plain-language glossary before a visit.

Sources

Looking for care? Find a PCOS/PMOS-focused provider or browse by state.

This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.